Olmesartan Medoxomil/Hydrochlorothiazide Accord Healthcare (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil/Hydrochlorothiazide Accord Healthcare, is an angiotensin II receptor blocker presented as a combination tablet for oral use. It treats hypertension, often in patients who require additional blood pressure control beyond what an ARB alone can provide.

GNH USA supplies Olmesartan Medoxil/Hydrochlorothiazide Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan Medoxil/Hydrochlorothiazide combines an ARB with a thiazide diuretic to manage high blood pressure and related cardiovascular risk. - Hypertension: lowers systolic and diastolic blood pressure when monotherapy is insufficient. - Hypertensive heart disease: reduces cardiac workload and helps prevent progression of left‑ventricular hypertrophy. - Chronic kidney disease with hypertension: aids in slowing renal function decline by controlling systemic pressure.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angio‑edema - Liver function abnormalities - Blood dyscrasias such as agranulocytosis

Before starting therapy, clinicians should assess patient history and monitor relevant parameters. - Renal function: evaluate baseline creatinine and eGFR, adjust if impaired. - Electrolytes: check potassium and sodium levels, especially with concomitant potassium‑sparing agents. - Pregnancy: avoid use; teratogenic risk is associated with ARBs. - Elderly patients: initiate at lower dose and monitor for orthostatic hypotension. - Drug‑induced photosensitivity: advise patients to limit excessive sun exposure. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Olmesartan Medoxil/Hydrochlorothiazide may interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): risk of renal impairment and hyperkalemia. - Potassium‑rich supplements or potassium‑sparing diuretics: may cause dangerous hyperkalemia. - Lithium: increased lithium levels leading to toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - ACE inhibitors or other ARBs: additive risk of hypotension and renal dysfunction. - Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment.